摘要
目的观察重组人白介素-11(IL-11)治疗鼻咽癌同步放化疗相关性口腔粘膜炎的疗效。方法将出现Ⅱ度或Ⅲ度口腔粘膜炎的60例鼻咽癌放化疗患者随机分为两组,观察组(白介素-11+常规治疗)和对照组(常规治疗)各30例。观察两组患者的治疗效果和疼痛缓解情况。结果观察组总的有效率为83.3%,对照组为60.0%,2组比较有统计学意义(=4.0219,P=0.0449)。进一步分析发现,2组在Ⅱ度口腔粘膜炎的疗效方面没有统计学意义(F=19,P=0.2263);在Ⅲ度的疗效中,观察组与对照组显示出统计学意义(F=6,P=0.0500)。在控制疼痛方面,2组比较有统计学意义(=4.0219,P=0.0449),观察组的疼痛缓解率明显高于对照组。结论重组人白介素-11控制急性放射性口腔粘膜炎疗效好,能够明显改善患者的生活质量,具有重要的临床实用价值。
Objective To observe the efficacy of recombinant human interleukin-11 （IL-11 ） in treatment of oral mucosi- tis related with nasopharyngeal carcinoma radioehemotherapy. Methods 60 patients of nasopharyngeal carcinoma with pathologi- cally confirmed were randomly divided into two groups： 30 patients in observation group （IL-11 gargle plus conventional therapy） and 30 cases in control group （conventional treatment）. Results The total effective rate was 83.3% in observation group, while the control group was 60. 0% , there was statistically significant in both groups （f = 4. 0219 , P = 0. 0449 ）. Further analysis found that there was not statistically significant for H degree of efficacy of oral mucositis in two groups （ F = 19, P = 0. 2263 ）. But in grade ]]I, showed statistical significance was observed both the observation group and control group（F = 6, P = 0. 0500）. In pain control, the two groups was statistically significant（ f = 4. 0219, P = 0. 0449） , the pain relief was significantly higher in the observation group. Conclusion Recombinant human interleukin-11 was effective and low toxicity in treatment of acute radiation mucositis and can significantly improve patient＇s quality of life. It is beneficial to the successful completion of radiochemotherapy and have important clinical value.
出处
《四川医学》
CAS
2011年第12期1884-1886,共3页
Sichuan Medical Journal
基金
南充市科技局项目(编号:2010SF20)
关键词
重组人白介素-11
鼻咽癌
口腔粘膜炎
recombinant interleukin-11
nasopharyngeal carcinoma
oral mucositis
